Literature DB >> 30418659

Lower-grade gliomas: the wrong target for bevacizumab.

David Schiff1, John F de Groot2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 30418659      PMCID： PMC6231203          DOI： 10.1093/neuonc/noy165

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  13 in total

1.  Quantitative analysis of microvascular changes in diffuse astrocytic neoplasms with increasing grade of malignancy.

Authors:  P Wesseling; J A van der Laak; M Link; H L Teepen; D J Ruiter
Journal:  Hum Pathol       Date:  1998-04       Impact factor: 3.466

2.  Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

Authors:  Olivier L Chinot; Wolfgang Wick; Warren Mason; Roger Henriksson; Frank Saran; Ryo Nishikawa; Antoine F Carpentier; Khe Hoang-Xuan; Petr Kavan; Dana Cernea; Alba A Brandes; Magalie Hilton; Lauren Abrey; Timothy Cloughesy
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

3.  A randomized trial of bevacizumab for newly diagnosed glioblastoma.

Authors:  Mark R Gilbert; James J Dignam; Terri S Armstrong; Jeffrey S Wefel; Deborah T Blumenthal; Michael A Vogelbaum; Howard Colman; Arnab Chakravarti; Stephanie Pugh; Minhee Won; Robert Jeraj; Paul D Brown; Kurt A Jaeckle; David Schiff; Volker W Stieber; David G Brachman; Maria Werner-Wasik; Ivo W Tremont-Lukats; Erik P Sulman; Kenneth D Aldape; Walter J Curran; Minesh P Mehta
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

4.  Salvage chemotherapy with bevacizumab for recurrent alkylator-refractory anaplastic astrocytoma.

Authors:  Marc C Chamberlain; Sandra Johnston
Journal:  J Neurooncol       Date:  2008-10-25       Impact factor: 4.130

5.  Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas.

Authors:  Annick Desjardins; David A Reardon; James E Herndon; Jennifer Marcello; Jennifer A Quinn; Jeremy N Rich; Sith Sathornsumetee; Sridharan Gururangan; John Sampson; Leighann Bailey; Darell D Bigner; Allan H Friedman; Henry S Friedman; James J Vredenburgh
Journal:  Clin Cancer Res       Date:  2008-11-01       Impact factor: 12.531

6.  Treatment and survival of low-grade astrocytoma in adults--1977-1988.

Authors:  B M McCormack; D C Miller; G N Budzilovich; G J Voorhees; J Ransohoff
Journal:  Neurosurgery       Date:  1992-10       Impact factor: 4.654

Review 7.  Survival of patients with well-differentiated astrocytomas diagnosed in the era of computed tomography.

Authors:  F T Vertosick; R G Selker; V C Arena
Journal:  Neurosurgery       Date:  1991-04       Impact factor: 4.654

8.  Bevacizumab for recurrent alkylator-refractory anaplastic oligodendroglioma.

Authors:  Marc C Chamberlain; Sandra Johnston
Journal:  Cancer       Date:  2009-04-15       Impact factor: 6.860

9.  Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.

Authors:  Martin J van den Bent; Martin Klein; Marion Smits; Jaap C Reijneveld; Pim J French; Paul Clement; Filip Y F de Vos; Antje Wick; Paul J Mulholland; Martin J B Taphoorn; Joanne Lewis; Michael Weller; Olivier L Chinot; Johan M Kros; Iris de Heer; Tina Verschuere; Corneel Coens; Vassilis Golfinopoulos; Thierry Gorlia; Ahmed Idbaih
Journal:  Lancet Oncol       Date:  2018-08-13       Impact factor: 41.316

10.  IDH mutation status is associated with distinct vascular gene expression signatures in lower-grade gliomas.

Authors:  Lei Zhang; Liqun He; Roberta Lugano; Kenney Roodakker; Michael Bergqvist; Anja Smits; Anna Dimberg
Journal:  Neuro Oncol       Date:  2018-10-09       Impact factor: 13.029
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.